As CRISPR therapies progress to the clinic, it is essential for the technology to become more precise, controlled, and characterized. Explore the potential of ribonucleoprotein (RNP) to deliver CRISPR materials more accurately, efficiently, and effectively, as well as the manufacturing challenges that require further attention.
An institute researching CRISPR-based genome editing required a custom, highly pure, ultra-low endotoxin nuclease. Learn how Aldevron's expertise in Cas9 expression and purification helped the institute demonstrate comparable editing of neurons and reduced immune responses compared to using AAV serotype 9 for delivery.
With benefits across applications — including transposons, HDR/CRISPR, viral vectors, and mRNA — nanoplasmids are designed to replace antiquated bacterial backbones, while eliminating antibiotic markers that can cause regulatory concerns. Experts address the opportunities of using nanoplasmids over traditional plasmids.
Gene and cell therapy developers face challenges when initiating clinical programs that rely on CRISPR technology. Learn about the manufacturing obstacles and how a robust understanding of the RNP’s critical process parameters and CQAs is crucial for ensuring product consistency, enhancing patient safety, and maintaining compliance.
Discover how manufacturing research-grade Cas enzymes in an ISO 13485 certified facility enables a seamless transition to a cGMP product as you progress into the clinic. Review the catalog of nucleases and how Aldevron is poised to support your projects from development through commercialization.
